Related Experiment Video
Updated: Jul 11, 2026
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Targeting the absence: homozygous DNA deletions as immutable signposts for cancer therapy
1Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA. avarsh@caltech.edu
Abstract:
Many cancers harbor homozygous DNA deletions (HDs). In contrast to other attributes of cancer cells, their HDs are immutable features that cannot change during tumor progression or therapy. I describe an approach, termed deletion-specific targeting (DST), that employs HDs (not their effects on RNA/protein circuits, but deletions themselves) as the targets of cancer therapy. The DST strategy brings together both existing and new methodologies, including the ubiquitin fusion technique, the split-ubiquitin assay, zinc-finger DNA-recognizing proteins and split restriction nucleases. The DST strategy also employs a feedback mechanism that receives input from a circuit operating as a Boolean OR gate and involves the activation of split nucleases, which destroy DST vector in normal (nontarget) cells. The logic of DST makes possible an incremental and essentially unlimited increase in the selectivity of therapy. If DST strategy can be implemented in a clinical setting, it may prove to be curative and substantially free of side effects.
Insights
This study introduces deletion-specific targeting (DST), a novel cancer therapy approach that utilizes immutable homozygous DNA deletions (HDs) as direct therapeutic targets. DST offers a highly selective and potentially curative treatment strategy with minimal side effects.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Many cancers exhibit homozygous DNA deletions (HDs), which are stable genetic alterations unaffected by tumor progression or treatment.
- Current cancer therapies often target dynamic cellular processes, leading to resistance and side effects.
- The immutability of HDs presents a unique opportunity for developing highly specific cancer treatments.
Purpose of the Study:
- To describe a novel therapeutic strategy, deletion-specific targeting (DST), that directly exploits homozygous DNA deletions (HDs) in cancer cells.
- To outline the methodologies and mechanisms underlying the DST approach for selective cancer therapy.
- To explore the potential of DST for achieving curative and side-effect-free cancer treatment.
Main Methods:
- Development of deletion-specific targeting (DST) strategy using HDs as direct therapeutic targets.
- Integration of existing and novel techniques, including ubiquitin fusion, split-ubiquitin assay, zinc-finger DNA-recognizing proteins, and split restriction nucleases.
- Implementation of a feedback mechanism with a Boolean OR gate to activate split nucleases, ensuring DST vector destruction in normal cells.
Main Results:
- The DST strategy leverages the immutable nature of HDs for precise targeting of cancer cells.
- The proposed system incorporates a safety mechanism to eliminate the DST vector in non-target (normal) cells.
- The DST logic allows for a theoretically unlimited increase in therapeutic selectivity.
Conclusions:
- Deletion-specific targeting (DST) represents a promising new paradigm for cancer therapy, directly utilizing homozygous DNA deletions (HDs).
- The DST strategy's inherent selectivity mechanism suggests potential for curative outcomes with significantly reduced side effects.
- Clinical implementation of DST could revolutionize cancer treatment by offering a highly targeted and safe therapeutic option.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...